• Je něco špatně v tomto záznamu ?

Cholinergic properties of new 7-methoxytacrine-donepezil derivatives

V. Sepsova, JZ. Karasova, G. Tobin, D. Jun, J. Korabecny, P. Cabelova, K. Janska, J. Krusek, K. Skrenkova, K. Kuca, O. Soukup,

. 2015 ; 34 (2) : 189-200.

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15022900

Organophosphorus nerve agents inhibit acetylcholinesterase (AChE) which causes the breakdown of the transmitter acetylcholine (ACh) in the synaptic cleft. Overstimulation of cholinergic receptors (muscarinic and nicotinic) by excessive amounts of ACh causes several health problems and may even cause death. Reversible AChE inhibitors play an important role in prophylaxis against nerve agents. The presented study investigated whether 7-methoxytacrine (7-MEOTA) and 7-MEOTA-donepezil derivatives can act as central and peripheral reversible AChE inhibitors and simultaneously antagonize muscarinic and nicotinic receptors. The possible mechanism of action was studied on cell cultures (patch clamp technique, calcium mobilization assay) and on isolated smooth muscle tissue (contraction study). Furthermore, the kinetics of the compounds were also examined. CNS availability was predicted by determining the passive blood-brain barrier penetration estimated via a modified PAMPA assay. In conclusion, this study provides promising evidence that the new synthesized 7-MEOTA-donepezil derivatives have the desired anticholinergic effect; they can inhibit AChE, and nicotinic and muscarinic receptors in the micromolar range. Furthermore, they seem to penetrate readily into the CNS. However, their real potency and benefit must be verified by in vivo experiments.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15022900
003      
CZ-PrNML
005      
20150729122854.0
007      
ta
008      
150709s2015 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/gpb_2014036 $2 doi
035    __
$a (PubMed)25504063
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Sepsova, Vendula $u Depatment of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. vendula.sepsova@unob.cz.
245    10
$a Cholinergic properties of new 7-methoxytacrine-donepezil derivatives / $c V. Sepsova, JZ. Karasova, G. Tobin, D. Jun, J. Korabecny, P. Cabelova, K. Janska, J. Krusek, K. Skrenkova, K. Kuca, O. Soukup,
520    9_
$a Organophosphorus nerve agents inhibit acetylcholinesterase (AChE) which causes the breakdown of the transmitter acetylcholine (ACh) in the synaptic cleft. Overstimulation of cholinergic receptors (muscarinic and nicotinic) by excessive amounts of ACh causes several health problems and may even cause death. Reversible AChE inhibitors play an important role in prophylaxis against nerve agents. The presented study investigated whether 7-methoxytacrine (7-MEOTA) and 7-MEOTA-donepezil derivatives can act as central and peripheral reversible AChE inhibitors and simultaneously antagonize muscarinic and nicotinic receptors. The possible mechanism of action was studied on cell cultures (patch clamp technique, calcium mobilization assay) and on isolated smooth muscle tissue (contraction study). Furthermore, the kinetics of the compounds were also examined. CNS availability was predicted by determining the passive blood-brain barrier penetration estimated via a modified PAMPA assay. In conclusion, this study provides promising evidence that the new synthesized 7-MEOTA-donepezil derivatives have the desired anticholinergic effect; they can inhibit AChE, and nicotinic and muscarinic receptors in the micromolar range. Furthermore, they seem to penetrate readily into the CNS. However, their real potency and benefit must be verified by in vivo experiments.
650    _2
$a zvířata $7 D000818
650    _2
$a kultivované buňky $7 D002478
650    _2
$a cholinergní antagonisté $x aplikace a dávkování $7 D018680
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a indany $x aplikace a dávkování $7 D007189
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a antagonisté muskarinových receptorů $x aplikace a dávkování $7 D018727
650    _2
$a kosterní svalová vlákna $x účinky léků $x metabolismus $7 D018485
650    _2
$a nikotinoví antagonisté $x aplikace a dávkování $7 D018733
650    _2
$a piperidiny $x aplikace a dávkování $7 D010880
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a takrin $x aplikace a dávkování $x analogy a deriváty $7 D013619
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Karasova, Jana Z
700    1_
$a Tobin, Gunnar
700    1_
$a Jun, Daniel
700    1_
$a Korabecny, Jan
700    1_
$a Cabelova, Pavla
700    1_
$a Janska, Katerina
700    1_
$a Krusek, Jan
700    1_
$a Skrenkova, Kristyna
700    1_
$a Kuca, Kamil
700    1_
$a Soukup, Ondrej
773    0_
$w MED00001896 $t General physiology and biophysics $x 0231-5882 $g Roč. 34, č. 2 (2015), s. 189-200
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25504063 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150729122940 $b ABA008
999    __
$a ok $b bmc $g 1083239 $s 905893
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 34 $c 2 $d 189-200 $i 0231-5882 $m General physiology and biophysics $n Gen Physiol Biophys $x MED00001896
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...